DDInter1905 DDInter856
Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978.
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated heparin is more specific than LMWH for thrombin. Furthermore, the effects of UH can typically be reversed by using protamine sulfate.
Urokinase {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capsicum
Urokinase {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ticagrelor
Urokinase {u} may lead to a major life threatening interaction when taken with {v} Dasatinib
Urokinase {u} may lead to a major life threatening interaction when taken with {v} Bivalirudin
Urokinase may cause a minor interaction that can limit clinical effects when taken with Capsicum
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor
Urokinase may lead to a major life threatening interaction when taken with Dasatinib
Urokinase may lead to a major life threatening interaction when taken with Bivalirudin